Association of Tryptophan Metabolites with Incident Type 2 Diabetes in the PREDIMED Trial: A Case–Cohort Study

According to the World Health Organization, type 2 diabetes comprises the majority of the more than 400 million people with diabetes around the world. In efforts to better understand the disease, metabolomics measurements have identified tryptophan metabolites as potential biological mediators in the development of type 2 diabetes. 
The PREDIMED trial was a multi-center trial of Mediterranean-style diets where the primary prevention of cardiovascular events that also included type 2 diabetes as a secondary end point. An original research article published in the August 2018 issue of Clinical Chemistry studies whether tryptophan metabolites in PREDIMED participants were associated with development of type 2 diabetes and insulin resistance.